+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Lupus Drug"

Cutaneous Lupus Erythematosus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Cutaneous Lupus Erythematosus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 47 Pages
  • Global
From
Chronic Cutaneous Lupus Erythematosus - Discoid Lupus Erythematosus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Chronic Cutaneous Lupus Erythematosus - Discoid Lupus Erythematosus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 40 Pages
  • Global
From
Loading Indicator

The Lupus Drug market is a subset of the Immune Disorders Drugs market, which focuses on treatments for autoimmune diseases such as lupus. Lupus is a chronic, autoimmune disorder that can cause inflammation, pain, and tissue damage in various parts of the body. Lupus drugs are used to reduce inflammation, suppress the immune system, and reduce the risk of organ damage. These drugs are typically prescribed in combination with other treatments such as lifestyle changes, physical therapy, and other medications. The Lupus Drug market is highly competitive, with a range of products available from both generic and branded manufacturers. Companies in the market include AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Pfizer, and Roche. Show Less Read more